参考文献/References:
[1]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.[2]Damman K,Valente MAE,Voors AA,et al.Renal impairment,worsening renal function,and outcome in patients with heart failure:an updated meta-analysis[J].European Heart Journal,2014,35(7):455-469.[3]Faris R,Flather MD,Purcell H,et al.Diuretics for heart failure[J].Cochrane Database Syst Rev,2016,2(2):CD003838.[4]Imamura T,Kinugawa K.Prognostic Impacts of Hyponatremia,Renal Dysfunction,and High-Dose Diuretics During a 10-Year Study Period in 4,087 Japanese Heart Failure Patients[J].International Heart Journal,2016,57(5):657-658.[5]姜晨煜,何也,傅强.心肾综合征的治疗现状及展望[J].广东医学,2018,39(10):1578-1582.[6]Hori M.Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure[J].Future Cardiology,2013,9(2):163-176.[7]王立立,韩爽,张至,等.不同剂量托伐普坦治疗老年慢性心力衰竭伴利尿剂抵抗患者的疗效与安全性观察[J].中华老年心脑血管病杂志,2019,21(4):375-378.[8]Kinugawa K,Sato N,Inomata T,et al.Efficacy and Safety of Tolvaptan in Heart Failure Patients With Volume Overload-An Interim Result of Post-Marketing Surveillance in Japan[J].Circulation Journal Official Journal of the Japanese Circulation Society,2014,78(4):844-852.[9]Tamaki S,Sato Y,Yamada T,et al.Tolvaptan Reduces the Risk of Worsening Renal Function in Patients With Acute Decompensated Heart Failure and Preserved Left Ventricular Ejection Fraction-Prospective Randomized Controlled Study[J].Circulation Journal Official Journal of the Japanese Circulation Society,2017,81(5):740.[10]Shirakabe A,Hata N,Yamamoto M,et al.Immediate Administration of Tolvaptan Prevents the Exacerbation of Acute Kidney Injury and Improves the Mid-Term Prognosis of Patients With Severely Decompensated Acute Heart Failure[J].Circulation Journal,2014,78(4):911-921.[11]Alskaf E,Tridente A,Al-Mohammad A.Tolvaptan for Heart Failure,Systematic Review and Meta-analysis of Trials[J].Heart,2016,102(Suppl 6):A1. [12]Uemura Y,Shibata R,Takemoto K,et al.Safety and Efficacy of Long-Term Use of Tolvaptan in Patients With Heart Failure and Chronic Kidney Disease[J].Circulation Journal,2017,81(11):1736.[13]Udelson JE,Mcgrew FA,Flores E,et al.Multicenter,Randomized,Double-Blind,Placebo-Controlled Study on the Effect of Oral Tolvaptan on Left Ventricular Dilation and Function in Patients With Heart Failure and Systolic Dysfunction[J].Journal of the American College of Cardiology,2007,49(22):2151-2159.
相似文献/References:
[1]郭俊林,张立.BNP对CRT后期疗效的临床评价[J].医学信息,2018,31(01):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
GUO Jun-lin,ZHANG li.Clinical Evaluation of BNP in Treatment of Late CRT[J].Medical Information,2018,31(15):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
[2]程 林.重组人脑利钠肽用于重症急性心肌炎伴
心力衰竭患者治疗的临床研究[J].医学信息,2018,31(08):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
CHENG Lin.Clinical Study of Recombinant Human Brain Natriuretic Peptide in the Treatment of Patients with Severe Acute Myocarditis and Heart Failure[J].Medical Information,2018,31(15):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
[3]胡丽君.螺内酯联合曲美他嗪治疗慢性心力衰竭的疗效分析[J].医学信息,2018,31(08):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
HU Li-jun.Efficacy of Spironolactone Combined with Trimetazidine in the Treatment of Chronic Heart Failure[J].Medical Information,2018,31(15):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
[4]李 铎,王建华.盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响[J].医学信息,2018,31(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Medical Information,2018,31(15):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
[5]何玲玲,程淑芬.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭疗效观察[J].医学信息,2018,31(13):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
HE Ling-ling,CHENG Shu-fen.Therapeutic Effect of Trimetazidine Combined with Metoprolol Succinate in the Treatment of Coronary Heart Disease with Heart Failure[J].Medical Information,2018,31(15):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
[6]赵 维,廖荣宏,王爱华.糖皮质激素治疗心力衰竭疗效与安全性的Meta分析[J].医学信息,2018,31(14):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
ZHAO Wei,LIAO Rong-hong,WANG Ai-hua.Meta-analysis of the Efficacy and Safety of Glucocorticoids in the Treatment of Heart Failure[J].Medical Information,2018,31(15):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
[7]施国富,吴春阳,施亚明,等.血浆脑钠肽对射血分数保留心力衰竭患者的诊断价值研究[J].医学信息,2018,31(16):47.[doi:10.3969/j.issn.1006-1959.2018.16.013]
SHI Guo-fu,WU Chun-yang,SHI Ya-ming,et al.Diagnostic Value of Plasma Brain Natriuretic Peptide in Patients with Heart Failure Preserved by Ejection Fraction[J].Medical Information,2018,31(15):47.[doi:10.3969/j.issn.1006-1959.2018.16.013]
[8]李 宁,胡硕强.心脏再同步治疗心力衰竭的文献计量分析[J].医学信息,2018,31(19):79.[doi:10.3969/j.issn.1006-1959.2018.19.024]
LI Ning,HU Shou-qiang.Bibliometric Analysis of Cardiac Resynchronization in the Treatment of Heart Failure[J].Medical Information,2018,31(15):79.[doi:10.3969/j.issn.1006-1959.2018.19.024]
[9]颜 琼,王 静,胡 聪.慢性心力衰竭患者半年内重返住院的调查分析与对策[J].医学信息,2018,31(20):173.[doi:10.3969/j.issn.1006-1959.2018.20.055]
YAN Qiong,WANG Jing,HU Cong.Investigation and Countermeasures of Patients with Chronic Heart Failure Returning to Hospital within Half a Year[J].Medical Information,2018,31(15):173.[doi:10.3969/j.issn.1006-1959.2018.20.055]
[10]杨锦龙,刘 欢.甲状腺激素测定在高血压心力衰竭患者中的临床意义[J].医学信息,2018,31(22):96.[doi:10.3969/j.issn.1006-1959.2018.22.026]
YANG Jin-long,LIU Huanc.Clinical Signifcance of Changes of Serum Thyroid Hormone Levels in Hypertensive Patients with Chronic Heart Failure[J].Medical Information,2018,31(15):96.[doi:10.3969/j.issn.1006-1959.2018.22.026]
[11]纪东华.托伐普坦治疗AMI合并心力衰竭的疗效及对患者血清hs-CRP、NT-proBNP表达的影响[J].医学信息,2019,32(16):127.[doi:10.3969/j.issn.1006-1959.2019.16.041]
JI Dong-hua.Efficacy of Tolvaptan in the Treatment of AMI Complicated with Heart Failure and its Effect on
Serum hs-CRP and NT-proBNP Expression[J].Medical Information,2019,32(15):127.[doi:10.3969/j.issn.1006-1959.2019.16.041]